Variable | Group | Start time Median (IQR) | 3rd month Median (IQR) | 9th month Median (IQR) | P |
---|---|---|---|---|---|
Ulnar NCV | Drug | 65 (9) | 42.5 (15.3) | 55 (17) | < 0.001 |
Placebo | 68.5 (5) | 40 (17.8) | 52 (18.5) | < 0.001 | |
Ulnar Amp | Drug | 6.1 (1) | 3 (2) | 5.4 (1.2) | < 0.001 |
Placebo | 6.4 (1) | 4 (1.5) | 5 (2) | < 0.001 | |
Median NCV | Drug | 60 (18.5) | 40 (18.5) | 50 (14.5) | < 0.001 |
Placebo | 60.5 (10) | 39 (17.5) | 49.5 (18.3) | < 0.001 | |
Median Amp | Drug | 5.2 (1.4) | 2.9 (2.1) | 4.1 (2) | < 0.001 |
Placebo | 5 (1.6) | 2.3 (2) | 4.3 (2.3) | < 0.001 | |
Tibial NCV | Drug | 53.5 (10) | 36.5 (16.5) | 45.5 (8.3) | < 0.001 |
Placebo | 55 (7.5) | 34.5 (19.3) | 47.5 (13.3) | < 0.001 | |
Tibial Amp | Drug | 3 (0.1) | 1.9 (1.3) | 2.4 (0.8) | < 0.001 |
Placebo | 3 (0.2) | 1.8 (1.2) | 2.5 (1) | < 0.001 | |
Proneal NCV | Drug | 54 (11.5) | 35 (13.3) | 42.5 (12.5) | < 0.001 |
Placebo | 54.5 (10.8) | 32 (11.5) | 43.5 (15.9) | < 0.001 | |
Proneal Amp | Drug | 3 (0.3) | 1.9 (1.3) | 2.3 (0.7) | < 0.001 |
Placebo | 3 (0.1) | 1.9 (0.9) | 2.1 (1) | < 0.001 |